{
    "title": "Madrigal leads race for NASH treatments after trial success, shares surge",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11554139/Madrigal-drug-meets-main-goals-awaited-NASH-trial.html",
    "date": "2022-12-19",
    "keywords": [
        "drug",
        "liver",
        "fibrosis",
        "resolution",
        "disease",
        "roy",
        "treatment",
        "resmetirom",
        "nash",
        "analyst",
        "improvement",
        "milligram",
        "dose",
        "placebo",
        "reporting",
        "latestage",
        "study",
        "forefront",
        "race",
        "drugmaker",
        "monday",
        "steatohepatitis",
        "fastestgrowing",
        "cause",
        "case",
        "scenario",
        "scarring",
        "goal",
        "lack",
        "ballooning",
        "inflammation",
        "consensus",
        "success",
        "endpoint",
        "probability",
        "madrigal",
        "akero",
        "form",
        "cirrhosis",
        "failure",
        "multibillion",
        "dollar",
        "market",
        "nordisk",
        "marketing",
        "application",
        "approval",
        "half",
        "trial",
        "worsening",
        "leo",
        "raghav",
        "mahobe",
        "krishna",
        "chandra",
        "eluri",
        "kuber"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}